Visceral leishmaniasis
Developing a new generation of treatments for one of the world’s leading parasitic killers
Visceral leishmaniasis
Developing a new generation of treatments for one of the world’s leading parasitic killers
We delivered four new treatments using existing drugs to make treatment shorter, safer, and more effective. We are now working to revolutionize the standard of care, advancing an unprecedented portfolio of all-new potential drugs to treat people suffering from all forms of the disease.
Visceral leishmaniasis – also known as kala-azar – causes fever, weight loss, spleen and liver enlargement, and, if not treated, death. HIV infection increases the severity of the disease, heightening people’s risk of dying from visceral leishmaniasis.
Post-kala-azar dermal leishmaniasis (PKDL) – a complication of visceral leishmaniasis that appears as a rash or skin condition months or years after successful visceral leishmaniasis treatment – is not deadly but can be disfiguring and stigmatizing.
In some regions affected by visceral leishmaniasis, treatments are poorly tolerated and lengthy, and can be toxic, painful, and costly.
‘I stopped going out, stopped playing with my friends fearing they would tease me. People told me my scars were permanent and would ruin my life as I will not get married. I don’t want to go through the trauma I underwent twice due to this disease’
What we have achieved
We have delivered new treatments using existing drugs to make treatments shorter, safer and more effective.
What we’re doing for people with visceral leishmaniasis
We are working to deliver better combination treatments and new drugs. Together with our partners, we have built an unprecedented portfolio of six new chemical classes, with different mechanisms of action against Leishmania parasites.
The long-term goal: entirely new, oral drugs
Our goal is to radically transform therapy by developing patient-friendly, simple oral therapies that are short, affordable, safe and effective in children and adults in all regions. A novel consortium bringing together pharmaceutical industry, academia, research institutes, and PDPs is building an unprecedented portfolio of promising drug candidates.
Making medical history for neglected patients
We develop urgently needed treatments for neglected patients and ensure they’re affordable, available, and adapted to the communities who need them
Stay connected
Get our latest news, personal stories, research articles, and job opportunities.
